IFI6 and breast carcinoma: The first data set, GSE11121, consisted of 78% ER+ cases (n = 200) and high G1P3 expression had an HR of 1.43 and the second data set contains 136 ER+ breast cancer patients who received tamoxifen as adjuvant therapy had an HR of 1.55 in high G1P3 cases (P = 0.001454).